What is the price range for the MoonLake Immunotherapeutics (MLTX) CFO’s share sales?

The filing explains that the 13,653 shares were sold in multiple trades at prices ranging from $19.50 to $20.83 per share. The reported transaction price of $20.02 represents the weighted average sale price across all those individual trades.

MoonLake Immunotherapeutics (MLTX) CFO logs pre-planned sale of 13,653 shares

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt sold 13,653 Class A ordinary shares in an open-market transaction. The shares were sold at a weighted average price of about $20.02 per share across multiple trades between $19.50 and $20.83. After this sale, he directly holds 1,172,431 Class A ordinary shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating it was scheduled in advance rather than timed opportunistically.

Insider Trade Summary 10b5-1

Net Seller: 13,653 shares ($273,333)

Net Sell 1 txn

Insider Bodenstedt Matthias

Role Chief Financial Officer

Sold 13,653 shs ($273K)

Type	Security	Shares	Price	Value
Sale	Class A ordinary shares, par value $0.0001 per share	13,653	$20.02	$273K

Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 1,172,431 shares (Direct, null)

Footnotes (1)

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.83. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 13,653 shares Weighted average sale price: $20.02 per share Sale price range: $19.50–$20.83 per share +2 more

5 metrics

Shares sold 13,653 shares Open-market sale on May 11, 2026

Weighted average sale price $20.02 per share Class A ordinary shares, open-market sale

Sale price range $19.50–$20.83 per share Multiple transactions within single reported sale

Shares held after transaction 1,172,431 shares Direct ownership by CFO after sale

Transaction date May 11, 2026 Date of open-market sale

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Class A ordinary shares, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

Class A ordinary shares financial

"Class A ordinary shares, par value $0.0001 per share"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/13/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bodenstedt Matthias

(Last)

(First)

(Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG

6300

(City)

(State)

(Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A ordinary shares, par value $0.0001 per share	05/11/2026		S⁽¹⁾		13,653	D	$20.02⁽²⁾	1,172,431	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.83. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

	/s/ Matthias Bodenstedt	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MoonLake Immunotherapeutics (MLTX) report on this Form 4?

MoonLake Immunotherapeutics reported that its Chief Financial Officer, Matthias Bodenstedt, sold 13,653 Class A ordinary shares. The sale was an open-market transaction executed under a Rule 10b5-1 trading plan, meaning it was pre-scheduled rather than a spontaneous trading decision.

How many MoonLake Immunotherapeutics (MLTX) shares did the CFO sell and at what price?

The CFO sold 13,653 Class A ordinary shares at a weighted average price of about $20.02 per share. The filing notes the trades occurred in multiple transactions, with prices ranging from $19.50 to $20.83 per share.

How many MoonLake Immunotherapeutics (MLTX) shares does the CFO hold after this sale?

Following the reported sale, the CFO directly holds 1,172,431 Class A ordinary shares. This context shows the transaction reduced his position by a relatively small portion compared with his remaining direct ownership stake in MoonLake Immunotherapeutics.

Was the MoonLake Immunotherapeutics (MLTX) CFO sale part of a Rule 10b5-1 plan?

Yes. The filing states the transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. These plans allow insiders to schedule trades in advance, helping separate routine liquidity moves from opportunistic trading.